Clinical-stage biopharmaceutical company SELLAS Life Sciences announces a proposed $150 million underwritten public offering of common stock on November 17, 2026.
Tag: public offering
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
Clinical-stage biopharmaceutical company SELLAS Life Sciences announces a proposed $150 million underwritten public offering of common stock on November 17, 2026.